Osiris Therapeutics, Inc. (NASDAQ:OSIR)

I scored on a couple of hold-my-nose green thumbs on Osiris last year so I thought I might give it a shot again as I drive for score leadership. Of course, the same strategy could put me in the cellar. Osiris continues to singlemindedly pursue a stem cell therapy that all available data indicates simply does not work. Right now there's a phase III trial of Prochymal in Crohn's that has already been terminated once for futility in an interim analysis, and phase II trials of Prochymal in acute MI and new onset diabetes with data expected in Q4 2011 or Q1 2012. A Prochymal submission to HealthCanada appears to be in regulatory limbo.

Now that I've completed the requisite disclaimer, I think it's more than likely that Osiris has a 10-15% rebound in them before more bad news hits. CAPS only, without a doubt.

stock picks with the potential of being doublers to multibaggers, yet risky, very risky and can go nearly to 0. hated by CAPs, but they have atleast 1 CAPs allstar that I like that has greenthumbed this one. These things have been beaten, and if 2 of 6 of em double, and another 2 don't even move, well it makes up if the last 2 go to zero n basically tank.
DMAN, FSLR, IDRA, ARQL, OSIR, MDVN

Unusually high call volume at $10 for 3/10

Stem cell company with partnership with Genzyme. Market value $220 million with cash $130 million. Percieved failure lead product trial tanked stock.

14 US$ 1 Nov 2009

I say it's time to get in on this stock.

So much money lost on their failed drug.

super option yields and a firm 10.00 bottom

New approval for phase III drug next week.

Best Bio Bets

The only stem company that makes money. Huge deal with Genzyme. They are ready to double.

With the Democrats in, this industry will receive a boost. I was "foolish" enough to sell this stock after a quick bounce shortly after its IPO. I am still a bit timid with this sector and its corresponding volatility...

Phase II data was exceptional.

This 'drug' (really cells) are the last in a line of options for patients dying of GVHD. If you don't know what GVHD is, you shouldn't rate this stock. The safety data thus far are exceptional, and if they have a little efficacy (and it looks like they have a lot), this will be a

This will be approved, and the use of the drug expanded rapidly.

At 15K per treatment (my numbers), they need a base of about 3500 patients to be a 500 million revenue.. should value at 5 bill or a 10 bagger...

Good luck

Stock that has beat the S&P 500 most of 2008 and insiders own more than 10 percent of the stock.

At $16, this stock is over priced. It has a lot of future potential but has very little profits to speak of. Their trials in adult stem research have shown major break troughs but are expensive. This stock should bloom with a more liberal president in office. In the short term, the stock is a $12-13 stock. In the long term, this stock will eventual explode IF they do not use all of their capital before FDA approval.

"Osiris was the God who made the seeds ripe for the harvesting, and also could raise those from the dead."

Osiris currently has some very promising stem cell treatments in the works including Prochymal, which could change the way diseases such as GVHD and Crohns are treated. They have some promising government contracts and Prochymal has been fast tracked by the FDA. I think this stock will take off starting in mid to late 2009.

medical

Burning cash like a rocket burning fuel at takeoff, Osiris is developing unique and much needed products. It may be several years before this stock takes off in the direction of ISRG but if they are successful in product development the potential is here. I believe adult stem cell research and development is the only ethical stem cell path and have put my money where my heart is!